1van der Feen C, Neijens FS, Kanters SD, et al. Angiographic distribution of lower extremity atheroselerosis in patients with and without diabetes[J]. Diabet Med,2002,19(5) :366--370.
2Scanu AM. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications [J]. Curr Atheroscler Rep,2003,5(2) :106-113.
3Rainwater DL,Kammerer CM. Lipoprotein Lp (a): effects of allelic variation at the LPA locus[J]. J Exp Zool, 1998,282 ( 1- 2): 54-61.
4Kraft HG, Lingenhel A,Koehl S. Apolipoprotein(a) kringle Ⅳ repeat number predicts risk for coronary heart disease [J]. Arterioseler Thromb Vase Biol,1996,16(6) :713-719.
5Koschinsky ML. Lipoprotein (a) and atherosclerosis:new perspectives on the mechanism of action of an enigmatic lipoprotein[J]. Curr Atheroscler Rep,2005,7(5) :389-395.
6Lima LM, Carvalho MG, Loures-Vale AA, et al. Increased serum levels of lipoprotein(a) correlated with the severity of coronary artery disease in patients submitted to angiography [J]. Arq Bras Cardiol,2006,87(3) :260-266.
7Cerrato P, Lmperiale D,Fomengo P, et al. Higher lipoprotein (a) levels in atherothrombotic than lacunar ischemic cerebrovascular disease [J]. Neurology, 2002,58 (4) : 653-655.
8Tseng CH. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan[J]. Diabetes Care,2004,27(2):517-521.
9Dieplinger B, Lingenhel A, Baumgartner N, et al. Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein ( a ) are associated with symptomatic peripheral arterial disease [J]. Clin Chem, 2007, 53(7):1298-1305.
10Nielsen LB, Nordestgaard BG, Stender S, et al. Transfer of lipoprotein(a) and LDL into aortic intima in normal and in cholesterol-fed rabbits[J]. Arterioscler Thromb Vasc Biol, 1995,15 (9) : 1492-1502.
3Sukhija R,Yalamanchili K,Aronowws,et al.Clinical characteristics rist factors,and medical treatment of 561 patients with peripheral arterial disease followed in an academic vascular surgery clinic.Carclial Rev,2005,13:108-110.
4Celermajer DS,Sorensen KE,Georgakopoulos D,etal.Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults.Circulation,1993,88:2149-2155.
6Stoffers HE,Rinkens PE,Kester AD,et al.The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease.Int J Emidemiol,1996,25:282-290.
7Criqui MH,Denenberg JO,Langer RD,et al.The epidemiology of peripheral arterial disease:importance of identifying the population at risk.Vasc Med,1997,2:221-226.
8Fowkes FG,Housley E,Riemersma RA,et al.Smoking,lipids,glucose intolerance,and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study.Am J Epidemiol,1992,135:331-340.
9Dormandy JA,Rutherford RB.Management of peripheral arterial disease (PAD).TASC Working Group.TransAtlantic InterSociety Consensus (TASC).J Vasc Surg,2000,31:S1-S296.
10Katsilambros NL,Tsapogas PC,Arvanitis MP,et al.Risk factors for lower extremity arterial disease in non-insulin-dependent diabetic persons.Diabet Med,1996,13:243-246.
6Hirsch AT, Criqui MH, Treat-Jaeobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care[J]. JAMA,2001,286(11):1317-1324.
7Brousseau ME, Schaefer EJ. New developments in the prevention of atherosclerosis in patients with low-high density lipoprotein cholesterol[J]. Curr Atheroseler Rep, 2001,3 (5) : 365-372.
8Habib SS,Aslam M,Naveed AK,et al.Lipoprotein(a)and glycaemic control in Pakistani subjects with diabetes mellitus[J].J Pak Med Assoc,2003,53(2):54-59.
9Hunninghake DB,McGovern ME,Koren M.A dose-ranging study of a new,once-daily,dual-component drug product containing niacin extended-release and lovastatin[J].Clin Cardiol,2003,26(3):112-118.
10Bogusevicius A,Gfinkevicius A,Maleckas A,et al.The role of D-dimer in the diagnosis of strangulated small-bowel obstruction[J].Medicina (Kaunas),2007,43(11):850-854.
